Cannabis is gaining wider public acceptance, with medical marijuana use legalized in 30 states and recreational use legalized in nine (plus Washinton D.C.). As recreational and medicinal use increases, the need for more efficient production of highly pure products will rise — and more sustainable alternatives to large-scale plant growth will further support a green bioeconomy. Enter synthetic biology: companies are already developing approaches to produce cannabinoid molecules — especially those that are naturally present at low levels in the cannabis plant — through industrial fermentation. Learn how synthetic biology can bring cannabinoids to the next level through applications ranging from pain relief and treatment of seizures to appetite suppression — or therapeutic applications that we haven’t yet dreamed of.
“Engineering strains of yeast that can produce these cannabinoids via fermentation is a perfect fit for our organism design platform and we are excited to be working with Cronos Group as they lead the way to high-quality cannabinoid treatments,” said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. READ MORE
Intrexon Corporation and Surterra Wellness Partner in $100M Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
Designed to enable the production of cannabinoids that only are produced today in miniscule amounts in cannabis plants as well as novel cannabinoids, yeast fermentation of cannabinoids provides advantages over conventional plant-based extraction. READ MORE